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Back to School Appointments?  
Think MRSA! 
Michelle L. Myer, MSN, RN, APRN, CPNP 
Epidemiology Nurse Consultant 
Division of Acute Disease Epidemiology 
As so many parents and healthcare providers 
learned last fall, community-acquired Methicillin-
resistant Staph. aureus (CA-MRSA) skin and soft 
tissue infections (SSTIs) are increasing in the 
school setting, especially among athletes.   
In the Fall and Winter of 2007, DHEC Regional Epi 
staff investigated 3 outbreaks of MRSA among 
high school football players.  MRSA may be easily 
spread among athletes via shared equipment, 
towels, hygiene items, and direct contact, 
especially among wrestlers. 
(Continued on page 5) 
Update on Salmonella Saintpaul 
Multistate Outbreak—South Carolina 
Perspective 
Summarized by Julie Schlegel, MSP 
Foodborne Epidemiologist 
Division of Acute Disease Epidemiology 
Between April 1 and August 28, 2008, 1,442 
persons infected with genetically identical 
Salmonella Saintpaul were identified in 43 states, 
the District of Columbia and Canada.  These cases 
were identified because clinical laboratories in all 
states send Salmonella strains from ill persons to 
their state public health laboratories for molecular 
characterization.   
The multistate Salmonella Saintpaul outbreak 
investigation has been a collaborative effort 
(Continued on page 2) 
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2008 Recommendations of the Advisory Committee on 
Immunization Practices (ACIP) Regarding Influenza 
Vaccine and Antiviral Agents 
Summary by Chasisity Springs, MSPH 
Influenza Epidemiologist 
Division of Acute Disease Epidemiology 
In the August 8, 2008, edition of the MMWR, the Advisory Committee on 
Immunization Practices (ACIP) issued several updated recommendations 
for this flu season:  
• Beginning with the 2008-2009 influenza season, annual 
immunization of all children 5-18 years of age is 
recommended.  Annual immunization of all children aged 5-18 
years should begin in September or as soon as vaccine is available 
for the 2008-09 influenza season, if feasible.  Annual immunization 
of all children aged 5-18 years of age should begin no later than 
during the 2009-10 influenza season. 
• Annual immunization of all children aged 6 months through 4 
years (59 months) of age and older children with conditions 
(Continued on page 12) 
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between states, the Centers for Disease Control 
and Prevention (CDC), the Food and Drug 
Administration (FDA), Health Canada and the 
Indian Health Service.  
An initial epidemiologic investigation in New 
Mexico and Texas comparing foods eaten by 
persons who were ill in May to foods eaten by well 
persons identified consumption of raw tomatoes 
as strongly linked to the illness.  This was a strong 
epidemiologic association, and tomatoes from that 
time period remained under investigation.  After 
the public warning concerning tomatoes on June 
7, cases continued to occur, though at a lower 
rate.  A similar but much larger, nationwide study 
comparing persons who were ill in June to well 
persons found that ill persons were more likely to 
have recently consumed raw tomatoes, raw 
jalapeño peppers, and raw cilantro.  These items 
were commonly, though not always, consumed 
together, so the study could not determine which 
item(s) caused the illnesses. 
After the first case-control study was conducted, 
clusters of infection were detected that were 
associated with specific restaurants.  Most clusters 
involved fewer than five ill persons.  As of July 1, 
three clusters had been investigated.  In one, 
illnesses were linked to consuming an item 
containing raw tomatoes and raw jalapeño 
peppers.  In the other two, illnesses were linked to 
an item containing raw jalapeño peppers but not 
the other suspect items.  
More recently, three additional clusters were 
investigated.  Detailed investigations of these 
clusters indicate that jalapeño peppers did not 
explain all illnesses.  In two of these 
investigations, illnesses were linked to an item 
containing raw serrano peppers and raw 
tomatoes, but not jalapeño peppers.  In the third, 
illnesses were linked to an item that contained raw 
jalapeños and tomatoes.  Other clusters are still 
under active investigation.  These epidemiological 
studies indicate that more than one food vehicle is 
involved in this outbreak.  No one food item can 
explain the entire outbreak.  Although rare, there 
have been outbreaks in the past in which more 
than one food source has been implicated. 
Only six people infected with this strain of 
Salmonella Saintpaul were identified in the 
country from April through June of 2007.  The 
previous rarity of this strain and the distribution of 
illnesses in all U.S. regions suggest that the 
implicated food is distributed throughout much of 
the country.  Because many persons with 
Salmonella illness do not have a stool specimen 
tested, it is likely that many more illnesses have 
occurred than those reported.  
In South Carolina, there have been two confirmed 
cases of Salmonella Saintpaul with the outbreak 
strain.  One case had consumed food at a North 
Carolina restaurant that had a cluster of cases 
related to the outbreak.  The second case sought 
medical care six weeks after onset of illness and 
could not recall specific food items consumed.  
However, DHEC characterizes each isolate of 
Salmonella sent to the DHEC Bureau of 
Laboratories (BOL) as part of routine surveillance 
to determine if cases are part of state or national 
outbreaks.  
At present, information indicates that jalapeño 
and serrano peppers grown, harvested, or packed 
in Mexico are the cause of some clusters and are 
(Continued from page 1) 
(Continued on page 3) 
Source: August 29, 2008 MMWR. 
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The Centers for Disease Control and Prevention 
(CDC) estimate that approximately 40,000 cases 
of salmonellosis are reported annually in the 
United States.  In South Carolina, physicians, 
laboratories and other partners report 
approximately 1200 cases of salmonellosis to 
DHEC each year. Because many milder cases are 
not diagnosed or reported, the actual number of 
salmonella infections may be 30 or more times 
greater.   
Salmonella bacteria live in the intestinal tracts of 
humans and other animals, including birds and 
reptiles. Salmonella infections are usually 
transmitted to humans by eating foods 
contaminated with animal feces.  Salmonella-
contaminated foods are typically of animal origin, 
such as poultry, beef, milk, or eggs; other foods 
have also been implicated in Salmonella 
outbreaks, as have the unwashed hands of 
infected food handlers. 
There are several key facets to Salmonella 
surveillance and response in SC: 
• Surveillance data are evaluated for an 
increase in reports in given population or 
geographic area.  This may identify 
potential outbreaks. 
(Continued on page 15) 
major food 
vehicles for the 
outbreak.  
Although 
tomatoes 
currently on the 
market are safe, 
raw tomatoes 
consumed early in 
the outbreak are 
still under 
investigation.  The 
outbreak strain 
Salmonella 
Saintpaul has 
been isolated 
twice from 
jalapeño peppers 
and once from 
serrano peppers.  
These foods were 
sampled as the 
result of traceback investigations based on the 
epidemiologic investigations of clusters. 
The CDC is continuing to collect data on cases of 
Salmonella Saintpaul and further updates may be 
forthcoming. 
Sources: 
http://www.cdc.gov/salmonella/saintpaul/, 
http://www.cdc.gov/mmwr/PDF/wk/mm5734.pdf 
(Continued from page 2) 
Update on Salmonella Saintpaul Multistate Outbreak—South Carolina Perspective 
Spotlight on Salmonella 
Julie Schlegel, MSP,  Foodborne Epidemiologist 
Division of Acute Disease Epidemiology 
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Back to School: Changes in the School and Childcare Exclusion Lists 
Michelle L. Myer, MSN, RN, APRN, CPNP 
Epidemiology Nurse Consultant 
Division of Acute Disease Epidemiology 
Each January, DHEC is required to publish lists of 
those health conditions that would exclude 
children and staff from school or out-of-home 
child care settings.  These Exclusion Lists, which 
also address attendance for individuals exposed to 
certain communicable illnesses or attending school 
or child care centers with on-going outbreaks, are 
available on the DHEC Bureau of Disease Control’s 
Web site, at: http://www.scdhec.gov/health/
disease/exclusion.htm. 
As a reminder, the School Exclusion List applies 
to most students in grades 1-12.  The Childcare 
Exclusion List applies to: 
• All children in out-of-home child care, 
• Children in 3-, 4-, or 5-year-old kindergarten, 
and 
• Medically fragile students in grades 1-12.   
For the purposes of school exclusion, “medically 
fragile students” are those with special 
healthcare needs or developmental delays who 
require close assistance with feeding or other 
personal hygiene activities by which 
communicable illnesses may easily be spread. 
The 2008-2009 School and Childcare Exclusion 
Lists were revised in January 2008, with 
changes effective July 1, 2008.  Revisions were 
based primarily on evolving literature on spread of 
methicillin-resistant Staph. aureas (MRSA) and 
other strep and staph infections in the school and 
child care setting.   
Some changes and clarifications include: 
• Content of medical and parent notes has been 
specified, to indicate the information needed 
by school and childcare centers to re-admit 
children. 
• Exclusion criteria for child care employees and 
children in child care have been placed side-by
-side for easier reference. 
• Exclusion is required for Campylobacter, until 
diarrheal symptoms are resolved. 
• School children with prolonged symptoms 
following completion of appropriate 
antimicrobial therapy for specified diarrheal 
illnesses (Campylobacter, Giardia, Salmonella 
or Shigella), may be readmitted if cleared by 
the student’s physician.  Negative culture 
requirements are still in place for children in 
child care with E. coli, Salmonella or Shigella 
infections. 
• Diarrheal exclusion criteria differ for 
elementary-aged children (first through fifth 
grades) and for older students in sixth through 
twelfth grades.  Older students with diarrhea, 
unless caused by E. coli, Salmonella or 
Shigella, do not have to be excluded unless 
they are thought to be contributing to the 
spread of illness in the school. 
• Exclusion is not required for students in sixth 
through twelfth grades with Tinea capitis or 
Tinea corporis unless they are thought to be 
contributing to the spread of illness in the 
school. 
• A great deal of detail has been added to the 
exclusion and readmission criteria for Staph 
and Strep skin infections to reflect updates in 
epidemiology of these infections in the 
community.  Antimicrobial therapy is not 
required for non-draining lesions, but children 
may not be re-admitted until lesions are 
showing signs of healing. 
• Exclusion is required for unimmunized children 
exposed to varicella (Chickenpox) from day 10 
to day 21 after the onset of rash in the person 
to whom they were exposed.  In an outbreak, 
exclusion would persist until day 21 after rash 
onset in the last person with varicella in the 
affected school.  DHEC should be consulted in 
cases where exclusion would be prolonged 
during outbreaks, especially outbreaks 
involving break-through cases of post-vaccine 
varicella.  For the 2008-209 school year, the 
varicella exclusion requirement applies to 
(Continued on page 5) 
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Guidance for the Public and Schools 
DHEC has posted, and continues to update, a 
webpage on MRSA, with guidance for parents, 
students, teachers, coaches and administrators.  
www.scdhec.gov/mrsa.htm.  Our staff has worked 
closely with school districts, via the SC Association 
of School Nurses (SCASN), and with private and 
parochial school via the SC Association of 
Independent Schools (SCISA.)  Providers may 
refer their patients with questions about CA-MRSs 
to this site, or to the CDC’s pages on MRSA:  
Guidance for Healthcare Providers 
DHEC is particularly interested in assuring prompt 
and appropriate treatment of skin and soft tissue 
infection, up to 50% of which may be resistant 
(Continued from page 1) Staph.  To this end, the SC DHEC Division of Acute 
Disease Epidemiology, working with experts in 
infectious disease from the USC school of 
Medicine, has developed a “Think MRSA” mini-
poster for clinicians.  A greatly reduced size 
version of the mini-poster is included in this issue 
of the Epi Notes (page 10).  8.5x11” and 11x17” 
version are available from DHEC’s MRSA page: 
www.scdhec.gov/mrsa.htm 
The recommendations found in the mini-poster are 
summarized from those developed by the Centers 
for Disease Control and Prevention, the American 
Medical Association, and the Infectious Diseases 
Society of America.   
“Outpatient Management of Skin and Soft 
Tissue Infections in the Era of Community-
associated MRSA” provides guidance for 
empirical management of SSTIs when CA-MRSA is 
a consideration.  Management options described 
include incision and drainage (I&D) of purulent, 
fluctuant or draining lesions, or lesions which can 
be aspirated. It describes empirical antibiotic 
treatment of cellulitis and other lesions without 
abscess.  The poster provides guidance for 
antimicrobial selection, and addresses special 
considerations for children.  There is also guidance 
addressing the role of decolonization in patients 
who have had repeated active infections. 
Reporting of CA-MRSA 
1. Clinical labs are required to report MRSA 
blood stream infections. 
2. MRSA skin and soft tissue infections are not 
reportable to DHEC unless they appear as 
part of a cluster or outbreak of illness. 
3. Outbreaks, or suspected outbreaks of CA-
MRSA skin and soft-tissue infections are 
reportable to DHEC immediately by phone. 
4. Individual cases of CA-MRSA occur 
commonly in all settings in the community 
and are not reportable. 
Back to School Appointments? Think MRSA! 
those students covered by the Varicella 
immunization requirement for school 
admission, or kindergarten through eighth 
graders. 
• Due to the resurgence of measles in the U.S., 
exclusion is now required for exposed 
unimmunized students for 21 days after 
onset of rash in the last case of measles in 
the affected school or community. 
DHEC has also revised its parent brochures, 
which may help clarify when children may need 
to be excluded from school or out-of-home child 
care.  These brochures also address appropriate, 
judicious use of antibiotics.  Parent brochures, 
which can be printed on legal paper for 
distribution to families, are found on the 
Exclusion List Web site: http://www.scdhec.gov/
health/disease/exclusion.htm. 
The Division of Acute Disease Epidemiology 
would appreciate feedback from healthcare 
providers about the School or Childcare 
Exclusion Lists.  The list will be revised at the 
end of January 2009 for the 2009-2010 school 
year.  Contact us at Exclusion@dhec.sc.gov. 
(Continued from page 4) 
Changes in the School & Childcare 
Exclusion Lists 
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1.  What are the new guidelines for post-
exposure prophylaxis for Hepatitis A? 
For decades, it has been common practice to use 
immune globulin (IG) for post-exposure 
prophylaxis (PEP) of hepatitis A.  However, last 
fall, the U.S. Public Health Service Advisory 
Committee on Immunization Practices (ACIP) 
recommended that hepatitis A vaccine could also 
be used for PEP.1  Careful reading 
of the ACIP's wording shows that 
IG is to be preferred in some 
instances, vaccines in others, but 
that in many (but not all!) 
circumstances both are considered 
acceptable (Table 1). 
 
(Continued on page 7) 
Table 1 (adapted from reference 1) 
Summary of updated recommendations for prevention of Hepatitis A (i) after 
exposure to hepatitis A virus, and (ii) in departing international travelers 
Postexposure prophylaxis:  People who recently have been exposed to HAV and who previously 
have not received hepatitis A vaccine should be administered a single dose of single-antigen 
hepatitis vaccine or immune globulin (IG) (0.02 mL/kg) as soon as possible. 
• For healthy people aged 12 months–40 years, single antigen hepatitis A vaccine at the age-
appropriate dose is preferred. 
• For adults aged >40 years, IG is preferred; vaccine can be used if IG cannot be obtained. 
• For children aged <12 months, immunocompromised persons, those who have been 
diagnosed with chronic liver disease, and people for whom vaccine is contraindicated, IG 
should be used. 
International travel:  All susceptible persons traveling to or working in countries that have high 
or intermediate hepatitis A endemicity should be vaccinated or receive IG before departure.  
Hepatitis A vaccine at the age-appropriate dose is preferred to IG.  The first dose of hepatitis A 
vaccine should be administered as soon as travel is considered. 
• One dose of single-antigen hepatitis A vaccine administered at any time before departure can 
provide adequate protection for most healthy persons. 
• Older adults, immunocompromised persons, and persons with chronic liver disease or other 
chronic medical conditions planning to depart to an area in £2 weeks should receive the initial 
dose of vaccine and also simultaneously can be administered IG (0.02 mL/kg) at a separate 
anatomic injection site. 
• Travelers who elect not to receive vaccine, are age <12 months, or are allergic to a vaccine 
component should receive a single dose of IG (0.02 mL/kg), which provides effective 
protection for up to three months. 
NOTE: Previous recommendations remain unchanged regarding (i) settings in which postexposure 
prophylaxis is indicated, and (ii) timing of administration of postexposure prophylaxis. 
Ask an Epi: New Recommendations for Post-Exposure Prophylaxis for Hepatitis A 
Eric R. Brenner, MD 
Medical Epidemiologist 
Division of Acute Disease Epidemiology 
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2.  What led the ACIP to modify its long-
standing recommendations for use of 
Immune globulin for Hepatitis A PEP? 
The rationale for the ACIP change offers an 
excellent example of the paradigm of “evidence 
based public health.”2 The chronology of the 
question runs like this: 
• Hepatitis A vaccine was licensed in 1995 
• In 1999, an Italian group published results of 
a randomized trial showing that PEP with 
hepatitis A vaccine was more effective than 
no PEP in preventing disease among 
household contacts.4 That study clearly 
demonstrated the utility of vaccine, but left 
open the question of how vaccine would 
compare to IG, the long-time standard! 
• Then, in 2007, a joint American-Kazakh team 
published results of another prospective 
randomized study conducted in Kazakhstan 
that showed nearly equivalent efficacy of 
vaccine and IG in preventing hepatitis A in 
household and day-care contacts.  5 This then 
became the key study, which allowed the 
ACIP to formulate its new guidelines.1 
3.  For what other infectious diseases can 
vaccine be effective in preventing disease 
even after exposure?   
Though vaccines are more commonly administered 
prior to exposure (Pre-exposure prophylaxis/
PrEP), several vaccines are effective in preventing 
disease even when administered after exposure 
(post-exposure prophylaxis/PEP).  Examples of 
vaccines for viral illnesses that can offer effective 
PEP are (i) smallpox, (ii) measles, (iii) hepatitis A, 
(iv) hepatitis B, (v) varicella and (vi) rabies.  
Tetanus provides a familiar example of an illness 
caused by a bacterium for which vaccine (tetanus 
toxoid) should be used as PEP in appropriate 
circumstances.”**  Full recommendations 
regarding use of vaccines for PEP can be found in 
the ACIP statements available online6 and, in 
more abbreviated format, in CDC's Epidemiology 
and Prevention of Vaccine-Preventable Diseases, 
also known as the “Pink Book.”7 These references 
also provide helpful summaries of the 
circumstances in which vaccines used for PEP are 
administered along with an appropriate 
immunoglobulin (e.g., HRIG, HBIG and TIG as 
part of the PEP regimens for rabies, hepatitis B 
and tetanus respectively.)   
Consultation regarding post-exposure prophylaxis 
for hepatitis A or other vaccine preventable 
diseases is available from the DHEC Bureau of 
Disease Control at (803) 898-0861. 
(Continued from page 6) 
New Recommendations for Hepatitis A Vaccine Use in Post Exposure Prophylaxis 
** Persons exposed to two other bacterial diseases, 
diphtheria and pertussis, should also receive post-
exposure doses of vaccine as appropriate.  
However, PEP for these conditions also includes an 
antibiotic (Benzathine penicillin for diphtheria, and 
a macrolide for pertussis) so that the efficacy of 
the PEP is shared, in varying proportions according 
to the biology of the circumstances, between the 
vaccine and the antimicrobial. 
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South Carolina 2007-2008 Influenza Season Surveillance Update 
Chasisity Springs, MSPH 
Influenza Epidemiologist 
Division of Acute Disease Epidemiology 
To help everyone prepare for the 2008-2009 
influenza season, which begins in October, we are 
providing a summary of South Carolina’s 2007-
2008 season.  Data were current as of mid-August 
2008.  The 2008-2009 flu season will begin on 
September 28, Week 40 of the Morbidity and 
Mortality Weekly Report (MMWR).   
South Carolina influenza surveillance consists of 
the following components: 
• Viral isolates 
• Influenza-like illness 
• Positive rapid antigen influenza tests 
• Enhanced human avian influenza surveillance, 
and 
• Influenza associated pediatric deaths. 
Influenza Culture Surveillance 
During the 2007-2008 flu season, 110 providers 
submitted specimens to DHEC’s Bureau of Labs 
(BOL) for testing.  BOL reported 446 culture-
confirmed cases of influenza: 362 influenza A 
(H3), 45 influenza A (H1) and 42 influenza B. 
ILI* Surveillance 
Thirty-three South Carolina counties have at least 
one enrolled influenza-like illness (ILI) sentinel 
provider.  Sentinel providers report to the Centers 
for Disease Control and Prevention each week the 
percentages of patients seen in their practices who 
presented with ILI.  Data were submitted at least 
once throughout the 2007-2008 season from 
(Continued on page 9) 
Chart 1: Percentage of visits for Influenza-like Illness (ILI) reported by Sentinel Providers in South Caro-
lina, 2006-2007 and 2007-2008 Influenza Seasons 
South Carolina’s ILI percentage remained above the South Atlantic baseline (2.1 percent) from 2008 
MMWR Week 04 through MMWR Week 10 (January 20 through March 8, 2008.)  
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Chart 2.  2006-2007 vs. 2007-2008 Positive Rapid Flu Tests in South Carolina 
South Carolina 2007-2008 Influenza Season Surveillance Update 
providers in 20 of these counties.  
Thirty-four providers actively participated in ILI 
surveillance in the 2007-2008 flu season.  This 
accounted for 43 percent of the enrolled providers.  
Of those who actively participated during the 
height of the flu season, approximately 15 percent 
have continued to report throughout the summer 
months.   
If you wish to participate in the viral isolate 
network, contact Nena Turner at (803) 896-0819 
to provide demographic info and license number.   
If you wish to participate in the ILI sentinel 
provider network, contact Chasisity Springs at 
(803) 898-0870.   
Please visit the DHEC Flu Monitoring Web site for 
weekly updated information: http://
www.scdhec.gov/health/disease/acute/flu.htm  
 
*  ILI, or influenza-like illness, is defined as fever 
>100° F AND cough or sore throat where no other 
explanation exists for these symptoms. 
(Continued from page 8) 
There were 30,221 positive rapid flu tests in the SC 2007-2008 flu season, compared to 15,914 in the 
2006-07 season.   
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Hospital Infection Disclosure Act (HIDA) 
Amber Taylor, MPH 
Hospital Infections Epidemiologist 
Division of Acute Disease Epidemiology 
What is HIDA? 
HIDA is the acronym for Hospital Infection 
Disclosure Act; it was passed by the SC State 
Legislature in May 2006. The statute, found in the 
SC Code of Laws, Chapter 7, Article 20, Title 44, is 
designed to assure that the public has access to 
information on hospital acquired infections in each 
hospital. HIDA requires hospitals to collect data on 
Hospital Acquired Infections (HAI) for specific 
procedures, which are determined by DHEC with 
the advice of the HIDA Advisory Committee. 
Reportable procedures are being phased in over 
time.  
Data are collected by a hospital’s infection control 
professional (ICP) and entered into the CDC’s 
National Healthcare Safety Network (NHSN).  Each 
hospital gives DHEC access to its NHSN data; 
these data are used to develop semi-annual HIDA 
reports as well as the detailed yearly analysis 
which is due February 1, 2009. 
What HAI information is HIDA collecting? 
Surgical Site Infections (SSIs) 
• Hysterectomies (abdominal and vaginal) 
• Cholecystectomy and cholecsystotomy 
(gallbladder surgery) 
• Hip prosthesis (replacement) 
• Knee prosthesis (replacement) 
• Coronary Artery Bypass Graft (chest only 
incision and chest/donor site incision) 
Blood Stream Infections 
• Central Line Associated Blood-stream 
Infections  
Central Line Associated Blood Stream 
Infections (CLABSIs) are monitored in medical-
surgical critical care units, pediatric critical care 
units and all inpatient locations, except long 
term acute care, in hospitals with < 150 beds.  
• MRSA Blood Stream Infections (MRSA BSIs) 
Reporting is required from clinical laboratories 
through paper reports, Carolina’s Health 
Electronic Surveillance System (CHESS) 
reporting on the web, or via Electronic 
Laboratory Reporting (ELRs).   
What are Infection Control Professionals 
required to do? 
ICPs are required to enter in NHSN all of the 
required reportable procedures and infections that 
pertain to their hospitals.  ICPs must put in a 
monthly reporting plan and do active surveillance 
for the procedures.   
For SSIs, the ICPs must ensure that basic 
demographic, procedure and risk data are entered 
for each reportable surgery for the month (i.e. 
patient ID, gender, birth date, procedure code, 
procedure date, and ASA class, wound class, etc) 
regardless of an infection occurring.  If a SSI 
occurs, then they are required to then put in 
event details pertaining to the infection.   
For CLABSIs, active surveillance means assuring 
that a daily count is taken at the same time each 
day of the number of patients with central lines in 
each location under surveillance (e.g., ICU), as 
well as the number of patients for that particular 
unit.  Additional information is required when a 
CLABSI occurs. 
How are the rates determined? 
SSI Rates are determined by the following 
equation: 
(Continued on page 12) 
Number of SSIs SSI rate per 100 
surgical procedures Number of surgical 
procedures 
* 100 = 
 
5 SSIs 3.3 SSI rate per 100 surgical procedures 
150 procedures 
* 100 = 
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MRSA BSI rates are determined for six month intervals by the following equation: 
(Continued from page 11) 
(Continued on page 13) 
Hospital Infection Disclosure Act 
5 MRSA BSI’s 
reported to DHEC 
for a 6-month 
reporting period 
2.27 MRSA 
bloodstream infection 
rate per 1,000 patient 
bed days 2200 patient bed 
days* in the same 
6-month period. 
* 1000 = 
Lab reports of 
MRSA BSI’s 
received in DHEC 
for a 6-month 
reporting period 
MRSA Bloodstream 
infection rate per 
1,000 patient bed 
days 
Number of hospital 
patient bed days* 
in the same 6-
month period 
* 1000 = 
that place them at increased risk for 
complications from influenza should 
continue.  Children and adolescents at high 
risk for influenza complications should continue 
to be a focus of immunization efforts as 
providers and programs transition to routinely 
immunizing all children. 
• Either TIV† or LAIV‡ may be used when 
immunizing healthy persons 2 through 49 
years of age.  LAIV should not be 
administered to children aged <5 years with 
possible reactive airways disease, such as 
those who have had recurrent wheezing or a 
recent wheezing episode.  Children with 
possible reactive airways disease, all persons 
at higher risk for influenza complications 
because of underlying medical conditions, 
children ages 6 to 23 months, and persons 
aged >49 years should receive TIV. 
• Children aged 6 months through 8 years 
should receive two doses of vaccine if they 
have not been immunized previously at any 
time with either LAIV or TIV (doses separated 
by >4 weeks); two doses are required for 
protection in these children.  Children aged 6 
months through 8 years who received only one 
dose in their first year of immunization should 
receive two doses the following year. 
• The 2008-09 trivalent vaccine virus strains are 
A/Brisbane/59/2007 (H1N1)-like, A/
Brisbane/10/2007 (H3N2)-like, and B/
Florida/4/2006-like antigens. 
• Oseltamivir-resistant influenza A (H1N1) 
strains have been identified in the United 
States and some other countries.  However, 
oseltamivir (Tamiflu, GSK) or zanamivir 
(Relenza, GSK) continue to be the 
recommended antivirals for treatment of 
influenza because other influenza virus strains 
remain sensitive to oseltamivir, and resistance 
levels to other antiviral medications remain 
high. 
Reference:  Centers for Disease Control and 
Prevention, (2008).  Prevention and control of 
influenza: recommendations of the Advisory 
Committee on Immunization Practices (ACIP), 
2008.  MMWR, 57(RR07), 1-60. 
Note: Brand names used in this article are for 
illustrative purposes.  DHEC does not endorse any 
companies or brands. 
† TIV: Trivalent inactivated influenza vaccine (flu shots)  
‡ LAIV: Live attenuated influenza vaccine, administered 
intranasally. 
(Continued from page 1) 
2008 Recommendations of the Advisory Committee on Immunization Practices (ACIP) 
Regarding Influenza Vaccine and Antiviral Agents 
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10 infections 
5.0 CLABSIs per 
1,000 central line 
days 
2000 central line 
days 
* 1000 = 
Number of CLABSI 
CLABSI Rate per 
1,000 central line 
days 
Number of central 
line days 
* 1000 = 
 
CLABSI rates are determined by the following 
equation:  
(Continued from page 12) Note: Hospital patient days are reported by the 
DHEC Office of Research and Statistics (ORS) 
hospital discharge database. 
Where can I find information on HIDA and 
the August 1, 2008 preliminary report?  
Information on HIDA is available at: 
www.scdhec.gov/health/disease/hai/.   
ACIP Influenza Vaccination Recommendations  
as Summarized in the August 8, 2008 MMWR 
Hospital Infection Disclosure Act 
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Summary of Conditions reported to SC DHEC January 1 through August 1, 2008.  
Compiled by Claire Youngblood, MA, Data Manager 
Division of Acute Disease Epidemiology 
Condition Confirmed Probable Total 
Animal Bite—PEP Recommended 245 0 245 
Aseptic meningitis 44 0 44 
Botulism, infant 1 0 1 
Brucellosis 1 1 2 
Campylobacteriosis 143 0 143 
Ciguatera fish poisoning 0 0 0 
Cryptosporidiosis 29 1 30 
Cyclosporiasis 0 0 0 
Dengue Fever 0 0 0 
Ehrlichiosis - human granulocytic 0 0 0 
Ehrlichiosis - human monocytic 0 0 0 
Ehrlichiosis - human- other & unspec 0 0 0 
Encephalitis - West Nile 0 0 0 
Enterohem. E. coli O157:H7 1 0 1 
Enterohem. E. coli shigatox+- ?serogrp 1 0 1 
Enterohem. E. coli- shigatoxin+- non-O157 0 0 0 
Giardiasis 77 0 77 
Group A Streptococcus- invasive 40 0 40 
Group B Streptococcus- invasive 25 0 25 
Haemophilus influenzae- invasive 34 1 35 
Hemolytic uremic syndrome - postdiarrheal 0 0 0 
Hepatitis A - acute 7 0 7 
Hepatitis B - acute 40 1 41 
Hepatitis B virus infection—Chronic 64 276 340 
Hepatitis B virus infection—Perinatal 0 0 0 
Hepatitis C - acute 3 0 3 
Hepatitis C Virus Infection- past or present 2468 99 2567 
Hepatitis Delta co- or super-infection- acute 0 0 0 
Hepatitis E - acute 0 0 0 
Influenza - human isolates 254 0 254 
Legionellosis 10 0 10 
Listeriosis 3 0 3 
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• In reported outbreaks, or where an 
increased background cases is identified, 
epidemiological interviews are conducted.  
These may identify potential sources of 
illness. 
• The DHEC Bureau of Laboratories serotypes 
all Salmonella isolates that are submitted 
to DHEC. 
• DNA fingerprinting (Pulsed Field Gel 
Electrophoresis) is completed for the 
majority of isolates submitted to DHEC. 
Local healthcare providers and reference 
laboratories are critical links between individual 
presenting patients and public health responses.  
Without reports of illness from local partners, 
DHEC could not identify and investigate outbreaks 
of public health significance.  South Carolina’s 
local disease reporters have provided key 
information in numerous outbreak investigations 
and in turn, critical product recalls.  
Reporting: Salmonellosis is reportable within 7 
days in South Carolina.  Please see the 2008 SC 
List of Reportable Conditions for more 
information: http://www.scdhec.gov/health/
disease/docs/reportable_conditions.pdf  
(Continued from page 3) 
Spotlight on Salmonella 
Summary of Conditions reported to SC DHEC January 1 through August 1, 2008  
Condition Confirmed Probable Total 
Neisseria meningitidis- invasive (Mening. disease) 16 1 17 
Pertussis 66 10 76 
Rocky Mountain spotted fever 4 17 21 
S. aureus, vancomycin intermediate susc (VISA) 0 0 0 
Salmonellosis 545 0 545 
Shiga toxin-producing Escherichia coli (STEC) 24 3 27 
Shigellosis 393 11 404 
Strep pneumoniae- invasive 358 0 358 
Streptococcal disease- invasive- other 1 0 1 
Tetanus 0 0 0 
Toxic-shock syndrome - staphylococcal 0 0 0 
Varicella (Chickenpox) 315 240 555 
Vibrio parahaemolyticus 1 0 1 
Vibrio spp. - non-toxigenic- other or unspecified 2 0 2 
Vibrio vulnificus infection 2 0 2 
West Nile Fever 0 0 0 
Yersiniosis 3 0 3 
Mumps 0 0 0 
Malaria 7 0 7 
Lyme disease 8 9 17 
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FOR DISEASE REPORTING 
For immediately reportable conditions, call your local county 
health department or, for after hours, call 1-888-847-0902.  
Routine reports may be phoned in to your local health 
department or mailed on a completed DHEC DISEASE 
REPORTING CARD (DHEC 1129.)  Local county health 
department numbers are listed on the Official List of 
Reportable Conditions.   
For a copy of the current Official List of Reportable 
Conditions, call 803-898-0861 or visit www.scdhec.gov/
health/disease.index.htm.  
Bureau of Disease Control 
J. Gibson, MD, MPH, Director 
803-898-0861 
Bureau of Disease Control Divisions 
Division of Acute Disease Epidemiology 
803-898-0861 
Division of Immunization 
1-800-277-4687 
Division of STD/HIV 
803-898-0749 
Division of Surveillance and Technical Support 
803-898-0749 
Division of Tuberculosis Control 
803-898-0558 
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